NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of NeuroVive Pharmaceutical (OTCMKTS:NEVPF) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. The firm currently has $0.25 target price on the stock.

According to Zacks, “NeuroVive Pharmaceutical AB is engaged in the research, discovery and development of mitochondrial-protecting pharmaceuticals. The company’s drug candidate consists of CicloMulsion(R) and NeuroSTAT(R) in clinical phases. CicloMulsion(R) is being studied for preoperative treatment of acute kidney injury coincident with major surgery and NeuroSTAT(R) is being studied for treating traumatic brain injury. NeuroVive Pharmaceutical AB is headquartered in Lund, Sweden. “

Shares of OTCMKTS:NEVPF opened at $0.19 on Tuesday. The business has a 50 day moving average price of $0.22 and a 200 day moving average price of $0.17. NeuroVive Pharmaceutical has a twelve month low of $0.10 and a twelve month high of $0.51. The company has a market cap of $9.94 million, a price-to-earnings ratio of -1.73 and a beta of 1.98.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases.

Recommended Story: What is total return in investing?

Get a free copy of the Zacks research report on NeuroVive Pharmaceutical (NEVPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NeuroVive Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroVive Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.